| Identification | Back Directory | [Name]
1H-Indole-2-carboxamide, 4,5,6,7-tetrahydro-3,6,6-trimethyl-N-[(1S)-1-[[[4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]carbonyl]pentyl]-4-oxo- | [CAS]
2648853-26-1 | [Synonyms]
G9a-IN-2
1H-Indole-2-carboxamide, 4,5,6,7-tetrahydro-3,6,6-trimethyl-N-[(1S)-1-[[[4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]carbonyl]pentyl]-4-oxo- | [Molecular Formula]
C30H42N4O4 | [MOL File]
2648853-26-1.mol | [Molecular Weight]
522.68 |
| Chemical Properties | Back Directory | [Boiling point ]
706.5±60.0 °C(predicted) | [density ]
1.167±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [pka]
13.17±0.70(predicted) |
| Hazard Information | Back Directory | [Uses]
G9a-IN-2 (Compound 7i) is an inhibitor for histone methyltransferases G9a with IC50 of 0.024 μM. G9a-IN-2 reduces H3K9me2 levels and induces the mRNA expression of γ-globin mRNA. G9a-IN-2 shows the potential in ameliorating sickle cell disease (SCD)[1]. | [References]
[1] Nishigaya Y, et al., Structure-based development of novel substrate-type G9a inhibitors as epigenetic modulators for sickle cell disease treatment. Bioorg Med Chem Lett. 2024 Jun 22;110:129856. DOI:10.1016/j.bmcl.2024.129856 |
|
|